These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31835809)

  • 1. Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
    Beckmann N; Becker KA; Kadow S; Schumacher F; Kramer M; Kühn C; Schulz-Schaeffer WJ; Edwards MJ; Kleuser B; Gulbins E; Carpinteiro A
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological manifestations of Farber disease in a new mouse model.
    Beckmann N; Kadow S; Schumacher F; Göthert JR; Kesper S; Draeger A; Schulz-Schaeffer WJ; Wang J; Becker JU; Kramer M; Kühn C; Kleuser B; Becker KA; Gulbins E; Carpinteiro A
    Biol Chem; 2018 Sep; 399(10):1183-1202. PubMed ID: 29908121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a Novel Acid Sphingomyelinase Activity Associated with Recombinant Human Acid Ceramidase.
    He X; Schuchman EH
    Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease.
    Ramsubir S; Nonaka T; Girbés CB; Carpentier S; Levade T; Medin JA
    Mol Genet Metab; 2008 Nov; 95(3):133-41. PubMed ID: 18805722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells.
    Levade T; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
    J Neurol Sci; 1995 Dec; 134(1-2):108-14. PubMed ID: 8747852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidase.
    Jenkins RW; Clarke CJ; Canals D; Snider AJ; Gault CR; Heffernan-Stroud L; Wu BX; Simbari F; Roddy P; Kitatani K; Obeid LM; Hannun YA
    J Biol Chem; 2011 Apr; 286(15):13292-303. PubMed ID: 21335555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfatide and sphingomyelin loading of living cells as tools for the study of ceramide turnover by lysosomal ceramidase--implications for the diagnosis of Farber disease.
    Levade T; Tempesta MC; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
    Biochem Mol Med; 1995 Apr; 54(2):117-25. PubMed ID: 8581356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staphylococcus aureus α-Toxin Induces Inflammatory Cytokines via Lysosomal Acid Sphingomyelinase and Ceramides.
    Ma J; Gulbins E; Edwards MJ; Caldwell CC; Fraunholz M; Becker KA
    Cell Physiol Biochem; 2017; 43(6):2170-2184. PubMed ID: 29069651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment.
    Yu FPS; Sajdak BS; Sikora J; Salmon AE; Nagree MS; Gurka J; Kassem IS; Lipinski DM; Carroll J; Medin JA
    Am J Pathol; 2019 Feb; 189(2):320-338. PubMed ID: 30472209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    Dworski S; Lu P; Khan A; Maranda B; Mitchell JJ; Parini R; Di Rocco M; Hugle B; Yoshimitsu M; Magnusson B; Makay B; Arslan N; Guelbert N; Ehlert K; Jarisch A; Gardner-Medwin J; Dagher R; Terreri MT; Lorenco CM; Barillas-Arias L; Tanpaiboon P; Solyom A; Norris JS; He X; Schuchman EH; Levade T; Medin JA
    Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):386-394. PubMed ID: 27915031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
    Zhang H; Nagree MS; Liu H; Pan X; Medin JA; Lipinski DM
    Gene Ther; 2023 Apr; 30(3-4):297-308. PubMed ID: 35902747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene.
    Alves MQ; Le Trionnaire E; Ribeiro I; Carpentier S; Harzer K; Levade T; Ribeiro MG
    Mol Genet Metab; 2013 Jul; 109(3):276-81. PubMed ID: 23707712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.
    Sikora J; Dworski S; Jones EE; Kamani MA; Micsenyi MC; Sawada T; Le Faouder P; Bertrand-Michel J; Dupuy A; Dunn CK; Xuan ICY; Casas J; Fabrias G; Hampson DR; Levade T; Drake RR; Medin JA; Walkley SU
    Am J Pathol; 2017 Apr; 187(4):864-883. PubMed ID: 28342444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Inhibition of Acid Sphingomyelinase Ameliorates Experimental Autoimmune Encephalomyelitis.
    Walter S; Gulbins E; Halmer R; Jahromi NH; Becker KA; Schottek A; Blatti C; Davies L; Schnoeder L; Bertsch T; Engelhardt B; Fassbender K
    Neurosignals; 2019; 27(S1):20-31. PubMed ID: 31778303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceramide accumulation is associated with increased apoptotic cell death in cultured fibroblasts of sphingolipid activator protein-deficient mouse but not in fibroblasts of patients with Farber disease.
    Tohyama J; Oya Y; Ezoe T; Vanier MT; Nakayasu H; Fujita N; Suzuki K
    J Inherit Metab Dis; 1999 Jun; 22(5):649-62. PubMed ID: 10399097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic ceramide accumulation leads to severe and varied pathological consequences.
    Alayoubi AM; Wang JC; Au BC; Carpentier S; Garcia V; Dworski S; El-Ghamrasni S; Kirouac KN; Exertier MJ; Xiong ZJ; Privé GG; Simonaro CM; Casas J; Fabrias G; Schuchman EH; Turner PV; Hakem R; Levade T; Medin JA
    EMBO Mol Med; 2013 Jun; 5(6):827-42. PubMed ID: 23681708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic stem cell transplantation leads to biochemical and functional correction in two mouse models of acid ceramidase deficiency.
    Rybova J; Sundararajan T; Kuchar L; Dlugi TA; Ruzicka P; McKillop WM; Medin JA
    Mol Ther; 2024 Oct; 32(10):3402-3421. PubMed ID: 39108096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiponectin overexpression improves metabolic abnormalities caused by acid ceramidase deficiency but does not prolong lifespan in a mouse model of Farber Disease.
    Norris MK; Tippetts TS; Wilkerson JL; Nicholson RJ; Maschek JA; Levade T; Medin JA; Summers SA; Holland WL
    Mol Genet Metab Rep; 2024 Jun; 39():101077. PubMed ID: 38595987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acid Ceramidase Depletion Impairs Neuronal Survival and Induces Morphological Defects in Neurites Associated with Altered Gene Transcription and Sphingolipid Content.
    Kyriakou K; Lederer CW; Kleanthous M; Drousiotou A; Malekkou A
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acid sphingomyelinase deficiency enhances myelin repair after acute and chronic demyelination.
    Chami M; Halmer R; Schnoeder L; Anne Becker K; Meier C; Fassbender K; Gulbins E; Walter S
    PLoS One; 2017; 12(6):e0178622. PubMed ID: 28582448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.